| 1 |
NCT00002494 |
Completed |
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia |
|
- Drug: cyclophosphamide
- Drug: cytarabine
- Drug: dexamethasone
- (and 11 more...)
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
134 |
All |
15 Years and older (Child, Adult, Senior) |
NCT00002494 |
CALGB-9251
U10CA031946
CLB-9251
CDR0000077643 |
|
May 1992 |
March 2004 |
January 2006 |
April 6, 2004 |
July 4, 2016 |
|
- University of California San Diego Cancer Center
La Jolla, California, United States - UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States - CCOP - Christiana Care Health Services
Wilmington, Delaware, United States - (and 20 more...)
|
| 2 |
NCT00049036 |
Completed
Has Results |
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma |
- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Immunoblastic Large Cell Lymphoma
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Small Noncleaved Cell Lymphoma
|
- Biological: rituximab
- Drug: etoposide
- Drug: doxorubicin hydrochloride
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment
|
106 |
All |
18 Years and older (Adult, Senior) |
NCT00049036 |
NCI-2012-02926
ECOG-AMC34
CDR0000257660
AMC-034
U01CA070019 |
|
March 2003 |
May 2009 |
May 2009 |
January 27, 2003 |
May 14, 2014 |
June 22, 2011 |
- AIDS - Associated Malignancies Clinical Trials Consortium
Rockville, Maryland, United States
|
| 3 |
NCT00022555 |
Completed |
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma |
- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Diffuse Mixed Cell Lymphoma
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Small Noncleaved Cell Lymphoma
|
- Drug: bryostatin 1
- Drug: vincristine sulfate
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of bryostatin-1 defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity
- Dose-limiting toxicities
- Immunomodulatory effects of this combination
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT00022555 |
NCI-2012-02398
AMC-029
U01CA070019
CDR0000068830 |
|
November 2001 |
July 2003 |
|
January 27, 2003 |
January 25, 2013 |
|
- AIDS - Associated Malignancies Clinical Trials Consortium
Rockville, Maryland, United States
|
| 4 |
NCT01959477 |
Completed |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- (and 142 more...)
|
- Drug: busulfan
- Drug: etoposide
- Drug: cyclophosphamide
- (and 2 more...)
|
Interventional |
Early Phase 1 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of performing real-time TDM, determined by the proportion of enrolled patients who are able to have an area under curve (AUC) for busulfan calculated
- Incidence of adverse events including mucositis, liver toxicity, seizures, and pulmonary toxicity, graded using NCI CTCAE version 4.0
- Proportion of patients who would not have achieved desired busulfan level with weight-based busulfan dosing
|
33 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01959477 |
CASE1412
NCI-2013-01829
CASE 1412
P30CA043703 |
|
March 2014 |
January 2015 |
April 2015 |
October 10, 2013 |
August 13, 2015 |
|
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 5 |
NCT01053494 |
Active, not recruiting |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Undifferentiated Leukemia
- Angioimmunoblastic T-cell Lymphoma
- (and 84 more...)
|
- Procedure: massage therapy
- Other: questionnaire administration
- Procedure: quality-of-life assessment
- (and 2 more...)
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility and acceptability of conducting a massage intervention with childhood cancer patients and their primary caregivers
- Effectiveness of caregiver massage to reduce child and caregiver distress and promote child health-related quality of life
|
80 |
All |
3 Years to 17 Years (Child) |
NCT01053494 |
CCCWFU 97709
NCI-2009-01456 |
|
April 2010 |
February 2012 |
|
January 21, 2010 |
June 1, 2017 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 6 |
NCT00112593 |
Completed
Has Results |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Undifferentiated Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- (and 176 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Procedure: peripheral blood stem cell transplantation
- (and 3 more...)
|
Interventional |
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Death From Regimen Toxicity or Opportunistic Infection
- Death From GVHD
- Successful Induction of Mixed Hematopoietic Chimerism as Assessed by the Percentage of Peripheral Blood T Cells That Are of Donor Origin
- (and 3 more...)
|
5 |
All |
up to 75 Years (Child, Adult, Senior) |
NCT00112593 |
1410.00
NCI-2010-00802
P30CA015704
P01CA018029 |
|
November 1999 |
November 2014 |
|
June 3, 2005 |
May 24, 2017 |
May 24, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 7 |
NCT00089011 |
Active, not recruiting
Has Results |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 171 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Drug: mycophenolate mofetil
- (and 4 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Grade III/IV GVHD
- Incidence of Chronic Extensive GVHD
- Incidences of Graft Rejection
- (and 5 more...)
|
150 |
All |
up to 74 Years (Child, Adult, Senior) |
NCT00089011 |
1898.00
NCI-2010-00267
P01CA078902
P30CA015704 |
|
April 2004 |
March 2014 |
October 1, 2018 |
August 5, 2004 |
January 2, 2018 |
May 22, 2017 |
- Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States - LDS Hospital
Salt Lake City, Utah, United States - VA Puget Sound Health Care System
Seattle, Washington, United States - (and 2 more...)
|
| 8 |
NCT00078858 |
Active, not recruiting |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 132 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- (and 4 more...)
|
Interventional |
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of life-threatening GVHD in patients undergoing a modified taper of post-grafting immunosuppression after undergoing nonmyeloablative HSCT from matched unrelated donors
- Need for corticosteroid treatment, defined as more than 1 mg/kg or equivalent of prednisone for more than 3 days at any time after transplant
- Graft rejection
- (and 2 more...)
|
37 |
All |
Child, Adult, Senior |
NCT00078858 |
1668.00
NCI-2012-00668
P30CA015704
P01CA018029 |
|
September 2003 |
January 2006 |
|
March 9, 2004 |
February 27, 2018 |
|
- Stanford University Hospitals and Clinics
Stanford, California, United States - Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - (and 7 more...)
|
| 9 |
NCT01793233 |
Active, not recruiting |
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas |
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- (and 127 more...)
|
- Other: questionnaire administration
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Comparison of the measures of ovarian reserve (AMH, FSH and E2) to that of health controls
- Degree of change in AMH, FSH, and E2 defined as the ratio of baseline minus end of therapy (EOT) measurement over baseline
- Degree of recovery of AMH, FSH, and E2 in the post-therapy phase
- Rate of AOF
|
205 |
Female |
up to 29 Years (Child, Adult) |
NCT01793233 |
ALTE11C1
NCI-2013-00069
COG-ALTE11C1
U10CA095861
UG1CA189955 |
|
June 2013 |
June 2019 |
June 2019 |
February 15, 2013 |
March 5, 2018 |
|
- City of Hope
Duarte, California, United States - Miller Children's Hospital
Long Beach, California, United States - Lucile Packard Children's Hospital Stanford University
Palo Alto, California, United States - (and 51 more...)
|
| 10 |
NCT00057811 |
Completed
Has Results |
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma |
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- (and 9 more...)
|
- Drug: doxorubicin hydrochloride
- Drug: cyclophosphamide
- Drug: methotrexate
- (and 11 more...)
|
Interventional |
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Grade ≥ 3 Stomatitis
- Response Rate
- Minimal Residual Disease
- Toxic Death
|
97 |
All |
1 Year to 29 Years (Child, Adult) |
NCT00057811 |
ANHL01P1
NCI-2009-00405
COG-ANHL01P1
CDR0000271941
U10CA098543 |
|
June 2004 |
October 2009 |
July 2014 |
April 9, 2003 |
September 19, 2014 |
August 22, 2014 |
- Children's Oncology Group
Arcadia, California, United States
|
| 11 |
NCT00458731 |
Completed |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- (and 59 more...)
|
- Biological: bevacizumab
- Drug: cediranib maleate
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and toxicity profile of combination bevacizumab and cediranib maleate
- Pharmacokinetic profile of oral cediranib maleate in combination with bevacizumab
|
57 |
All |
15 Years and older (Child, Adult, Senior) |
NCT00458731 |
NCI-2009-00184
MDACC 2005-0910
CDR0000538277
7534
P30CA016672
U01CA062461 |
|
May 2007 |
December 2013 |
|
April 11, 2007 |
February 19, 2014 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
| 12 |
NCT00005811 |
Completed |
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment |
- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Diffuse Mixed Cell Lymphoma
- AIDS-related Diffuse Small Cleaved Cell Lymphoma
- (and 17 more...)
|
- Drug: topotecan hydrochloride
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- For the leukemia and lymphoma patients, an objective response rate, defined to be the proportion of Complete Responses of less than 0.10
- For the patients with solid tumors, a proportion of patients who do not experience an event, defined to be death, progressive disease, relapse, or second malignancy of less than 0.3
- Safety and toxicity
- Concentration of matrix metalloproteinases in the CSF
|
77 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00005811 |
NCI-2012-01848
P9962
U10CA098543
CDR0000067813 |
|
April 2000 |
April 2006 |
February 2009 |
January 27, 2003 |
February 21, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
| 13 |
NCT01775475 |
Suspended |
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma |
- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Diffuse Mixed Cell Lymphoma
- AIDS-related Diffuse Small Cleaved Cell Lymphoma
- (and 6 more...)
|
- Drug: cyclophosphamide
- Drug: doxorubicin hydrochloride
- Drug: vincristine sulfate
- (and 5 more...)
|
Interventional |
Phase 2 |
- AIDS Malignancy Consortium
- National Cancer Institute (NCI)
- The EMMES Corporation
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Overall response rate
- Progression-free survival
- (and 5 more...)
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT01775475 |
AMC-068
NCI-2012-01695
U01CA121947 |
|
September 2016 |
January 2021 |
January 2021 |
January 25, 2013 |
December 21, 2017 |
|
- Moi Teaching and Referral Hospital
Eldoret, Kenya - University of Zimbabwe College of Health Sciences
Harare, Zimbabwe
|
| 14 |
NCT01769911 |
Withdrawn |
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma |
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Diffuse Mixed Cell Lymphoma
- (and 42 more...)
|
- Drug: carmustine
- Drug: cytarabine
- Drug: melphalan
- (and 5 more...)
|
Interventional |
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of infusion of gene-modified cells, measured by grade 3 or greater toxicities related to infusion of gene-modified cells using the Common Toxicity Criteria version 4.0(CTCv.4)
- Safety of O6BG/BCNU in vivo selection, defined as less than 25% of patients developing grade 3 or greater non-hematopoietic toxicity or grade 4 CTCv.4 hematopoietic toxicity
- Safety of structured treatment interruption defined as no decline in CD4 count by more than 25%, no HIV RNA more than 10,000 copies/mL; and no elevation of immune activation markers
- (and 3 more...)
|
0 |
All |
18 Years to 66 Years (Adult, Senior) |
NCT01769911 |
2583.00
NCI-2012-03168
P30CA015704 |
|
February 2015 |
February 2019 |
|
January 17, 2013 |
May 7, 2015 |
|
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 15 |
NCT01839916 |
Active, not recruiting |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- (and 61 more...)
|
- Biological: therapeutic allogeneic lymphocytes
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- University of Chicago
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who are able to receive at least one DLI treatment
- Progression free survival
- Overall survival
- (and 3 more...)
|
78 |
All |
14 Years to 75 Years (Child, Adult, Senior) |
NCT01839916 |
12-1191
NCI-2013-00782 |
|
April 4, 2013 |
July 2018 |
August 2018 |
April 25, 2013 |
February 8, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
|
| 16 |
NCT01760655 |
Recruiting |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- (and 65 more...)
|
- Drug: Fludarabine phosphate
- Drug: Thiotepa
- Radiation: Total body irradiation
- (and 6 more...)
|
Interventional |
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Overall survival
- Incidence of Regimen Related Toxicity
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT01760655 |
12D.501
2012-67 |
|
December 24, 2012 |
December 2019 |
January 2020 |
January 4, 2013 |
March 6, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 17 |
NCT01748721 |
Completed |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- (and 43 more...)
|
- Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- Morphotek
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Industry / NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (DLT) graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Incidence of toxicities, graded according to NCI CTCAE version 4.0
|
27 |
All |
13 Months to 21 Years (Child, Adult) |
NCT01748721 |
ADVL1213
NCI-2012-01702
U01CA097452 |
|
November 2013 |
May 2015 |
May 2015 |
December 12, 2012 |
January 8, 2016 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Children's Hospital of Orange County
Orange, California, United States - University of California San Francisco Medical Center - Parnassus
San Francisco, California, United States - (and 17 more...)
|
| 18 |
NCT01158274 |
Completed |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- AIDS-related Diffuse Large Cell Lymphoma
- (and 83 more...)
|
- Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
- Drug: capecitabine
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of RO4929097 and capecitabine, defined as that dose level at which less than one-third of patients experience a dose-limiting toxicity (DLT) graded according to NCI CTCAE version 4.0 (Part 1)
- Incidence of adverse events graded according to NCI CTCAE version 4.0 (Part 1)
- Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b)
- (and 6 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01158274 |
NCI-2012-02918
CDR0000680610
CO09907
8515
U01CA062491
U01CA132123
P30CA014520 |
|
June 2010 |
August 2012 |
|
July 8, 2010 |
November 7, 2014 |
|
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States - University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
|
| 19 |
NCT01529827 |
Active, not recruiting
Has Results |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 75 more...)
|
- Drug: fludarabine phosphate
- Drug: melphalan
- Radiation: total-body irradiation
- (and 6 more...)
|
Interventional |
Phase 2 |
- Roswell Park Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Transplant Related Mortality (TRM)
- Clinical Response
- Progression Free Survival (PFS) at One Year
- Median Time to Neutrophil Engraftment
|
94 |
All |
3 Years to 75 Years (Child, Adult, Senior) |
NCT01529827 |
I 177110
NCI-2011-03563 |
|
February 28, 2012 |
May 28, 2015 |
May 1, 2018 |
February 9, 2012 |
September 12, 2017 |
July 2, 2017 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
| 20 |
NCT01427881 |
Completed
Has Results |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 65 more...)
|
- Drug: cyclophosphamide
- Drug: cyclosporine
- Procedure: peripheral blood stem cell transplantation
- (and 4 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Chronic GVHD Requiring Systemic Immunosuppressive Treatment
- Donor Engraftment
- Grades II-IV and III-IV Acute GVHD
- (and 7 more...)
|
43 |
All |
up to 65 Years (Child, Adult) |
NCT01427881 |
2541.00
NCI-2011-02459
P30CA015704 |
|
September 2011 |
June 2014 |
July 2015 |
September 2, 2011 |
May 19, 2017 |
May 19, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 21 |
NCT00890747 |
Completed |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Acute Undifferentiated Leukemia
- (and 82 more...)
|
- Drug: sunitinib malate
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Grades 3, 4, and 5, treatment-related adverse events, graded according to the National Cancer Institute (NCI) CTCAE version 3.0
- Dose-limiting toxicity (DLT) defined as an adverse event that is possibly related to the study medication, graded according to the NCI CTCAE version 3.0
- Evaluation of response
- (and 2 more...)
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT00890747 |
NCI-2012-02208
AMC-061
U01CA121947 |
|
August 2009 |
May 2011 |
|
April 30, 2009 |
March 17, 2014 |
|
- Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Lombardi Comprehensive Cancer Center at Georgetown University
Washington, District of Columbia, United States - Northwestern University
Chicago, Illinois, United States - (and 8 more...)
|
| 22 |
NCT01305200 |
Completed
Has Results |
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant |
- Childhood Acute Lymphoblastic Leukemia in Remission
- Childhood Acute Myeloid Leukemia in Remission
- Childhood Chronic Myelogenous Leukemia
- (and 24 more...)
|
- Drug: supersaturated calcium phosphate rinse
- Other: placebo
- Other: questionnaire administration
- Procedure: quality-of-life assessment
|
Interventional |
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Supportive Care
|
- Duration of Severe Oral Mucositis (WHO Grade 3 or 4)
- Incidence of Severe Oral Mucositis
- Oral Mucositis Daily Questionnaire (OMDQ)
- (and 8 more...)
|
226 |
All |
4 Years to 21 Years (Child, Adult) |
NCT01305200 |
ACCL1031
NCI-2011-02635
CDR0000695718
COG-ACCL1031
U10CA095861 |
|
March 2011 |
June 2015 |
June 30, 2015 |
February 28, 2011 |
May 9, 2017 |
May 9, 2017 |
- Children's Oncology Group
Arcadia, California, United States - City of Hope
Duarte, California, United States - Children's Hospital and Research Center at Oakland
Oakland, California, United States - (and 32 more...)
|
| 23 |
NCT01231919 |
Completed |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Leukemias of Ambiguous Lineage
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
- (and 48 more...)
|
- Drug: Akt inhibitor MK2206
- Other: diagnostic laboratory biomarker analysis
- Other: pharmacological study
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD and/or recommended phase 2 dose of Akt inhibitor MK2206 determined according to incidence of dose-limiting toxicities (DLTs) graded using CTCAE v4.0 (Part A)
- Pharmacokinetic (PK) parameters of Akt inhibitor MK-2206
- Antitumor activity assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1
- (and 2 more...)
|
45 |
All |
1 Year to 21 Years (Child, Adult) |
NCT01231919 |
NCI-2011-02612
CDR0000687929
COG-ADVL1013
ADVL1013
U01CA097452 |
|
January 2011 |
April 2013 |
|
November 1, 2010 |
April 29, 2014 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Childrens Hospital of Orange County
Orange, California, United States - University of California San Francisco Medical Center-Parnassus
San Francisco, California, United States - (and 22 more...)
|
| 24 |
NCT01093586 |
Completed |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Megakaryoblastic Leukemia (M7)
- (and 73 more...)
|
- Procedure: double-unit umbilical cord blood transplantation
- Other: cytogenetic analysis
- Procedure: bone marrow aspiration
- (and 9 more...)
|
Interventional |
Phase 2 |
- Case Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Hematologic engraftment
- Disease-free and overall survival
- (and 8 more...)
|
14 |
All |
12 Years to 64 Years (Child, Adult) |
NCT01093586 |
CASE3Z07
NCI-2009-01319 |
|
March 2009 |
December 2015 |
December 2015 |
March 26, 2010 |
December 21, 2015 |
|
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 25 |
NCT01088763 |
Terminated |
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germinoma
- (and 43 more...)
|
- Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
- Other: diagnostic laboratory biomarker analysis
- Other: pharmacological study
- Drug: dexamethasone
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of RO4929097 determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
- MTD of RO4929097 administered with dexamethasone determined according to DLTs graded using CTCAE v4.0
- Antitumor activity of RO4929097 with or without dexamethasone assessed by Response Evaluation Criteria for Solid Tumors (RECIST)
|
129 |
All |
1 Year to 21 Years (Child, Adult) |
NCT01088763 |
NCI-2011-02024
COG-ADVL0919
CDR0000667505
ADVL0919
U01CA097452 |
|
March 2010 |
May 2011 |
May 2011 |
March 17, 2010 |
November 5, 2014 |
|
- Lucile Packard Children's Hospital Stanford University
Palo Alto, California, United States - Stanford University Hospitals and Clinics
Stanford, California, United States - Lurie Children's Hospital-Chicago
Chicago, Illinois, United States - (and 9 more...)
|
| 26 |
NCT00994500 |
Completed |
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germ Cell Tumor
- (and 32 more...)
|
- Drug: vorinostat
- Drug: bortezomib
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT according to NCI CTCAE version 3.0
- Disease response assessed according to RECIST criteria
|
20 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00994500 |
NCI-2011-01980
ADVL0916
CDR0000656719
COG-ADVL0916
U01CA097452 |
|
August 2009 |
July 2011 |
|
October 14, 2009 |
July 2, 2013 |
|
- Childrens Memorial Hospital
Chicago, Illinois, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Columbia University Medical Center
New York, New York, United States - (and 3 more...)
|
| 27 |
NCT00933985 |
Terminated |
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia |
- Acute Leukemias of Ambiguous Lineage
- Acute Undifferentiated Leukemia
- Angioimmunoblastic T-cell Lymphoma
- (and 26 more...)
|
- Drug: dexrazoxane hydrochloride
- Drug: doxorubicin hydrochloride
- Drug: obatoclax mesylate
- (and 3 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose of obatoclax mesylate in combination with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride, defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity
- Incidence of adverse events characterized by grade, relationship to study therapy, and prior experience, assessed by NCI CTCAE v4.0
- Disease response assessed using Response Evaluation Criteria in Solid Tumors
|
22 |
All |
up to 21 Years (Child, Adult) |
NCT00933985 |
NCI-2011-01936
COG-ADVL0816
CDR0000647160
ADVL0816
U01CA097452 |
|
June 2009 |
April 2013 |
April 2013 |
July 8, 2009 |
May 1, 2014 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Childrens Hospital of Orange County
Orange, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 17 more...)
|
| 28 |
NCT00867529 |
Completed
Has Results |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
- B-cell Adult Acute Lymphoblastic Leukemia
- B-cell Childhood Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- (and 35 more...)
|
- Biological: rituximab
- Procedure: peripheral blood stem cell transplantation
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- (and 2 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- American Cancer Society, Inc.
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Relapse Rate
- Incidence and Severity of Acute and Chronic GVHD Evaluated Per an Adapted Version of Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0
- Overall Survival and Progression-free Survival
- (and 2 more...)
|
63 |
All |
Child, Adult, Senior |
NCT00867529 |
2226.00
NCI-2010-00107
2226
P01CA078902
P30CA015704 |
|
February 2009 |
March 2015 |
March 26, 2015 |
March 23, 2009 |
January 2, 2018 |
May 22, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 29 |
NCT00856388 |
Active, not recruiting
Has Results |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
- Adult Acute Lymphoblastic Leukemia in Remission
- (and 97 more...)
|
- Drug: fludarabine phosphate
- Drug: melphalan
- Radiation: total-body irradiation
- (and 2 more...)
|
Interventional |
Not Applicable |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Day 100 TRM
- Median Time to ANC Engraftment
- Median Time to Platelet Engraftment
- (and 4 more...)
|
62 |
All |
3 Years to 75 Years (Child, Adult, Senior) |
NCT00856388 |
I 118807
NCI-2009-01508 |
|
January 14, 2009 |
August 9, 2012 |
August 15, 2019 |
March 5, 2009 |
December 26, 2017 |
June 13, 2016 |
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
| 30 |
NCT00795769 |
Completed
Has Results |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 101 more...)
|
- Drug: ondansetron
- Other: survey administration
- Procedure: management of therapy complications
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)
|
49 |
All |
21 Years and older (Adult, Senior) |
NCT00795769 |
2247.00
NCI-2010-00325 |
|
August 8, 2008 |
June 9, 2009 |
June 10, 2009 |
November 21, 2008 |
May 23, 2017 |
May 23, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 31 |
NCT00536601 |
Active, not recruiting |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- (and 56 more...)
|
- Drug: etoposide
- Drug: cyclophosphamide
- Drug: carmustine
- (and 7 more...)
|
Interventional |
Not Applicable |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival distribution of patients with HL, NHL, and MM for each disease-specific high-dose therapy regimen
- Progression-free survival distribution of patients with amyloidosis, acute leukemia, and selected solid tumors for each disease-specific high-dose therapy regimen
- Regimen-related toxicity
- (and 2 more...)
|
174 |
All |
4 Years and older (Child, Adult, Senior) |
NCT00536601 |
I 72806
NCI-2011-00131
P30CA016056 |
|
June 29, 2006 |
April 18, 2022 |
April 18, 2022 |
September 28, 2007 |
April 6, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States
|
| 32 |
NCT00408681 |
Completed
Has Results |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 111 more...)
|
- Drug: lithium carbonate
- Other: laboratory biomarker analysis
|
Interventional |
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Functional Recovery
- Duration of Treatment With the Study Product
- Mucosal Anatomic Recovery
- (and 4 more...)
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00408681 |
2080.00
NCI-2010-00269 |
GVHD |
June 2006 |
November 2010 |
May 1, 2015 |
December 7, 2006 |
March 7, 2017 |
January 20, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 33 |
NCT00363272 |
Completed |
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma |
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Choroid Plexus Tumor
- (and 22 more...)
|
- Drug: ispinesib
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT, graded according to NCI CTCAE version 3.0
|
30 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00363272 |
NCI-2012-01828
ADVL0517
U01CA097452
CDR0000491407 |
|
June 2006 |
October 2008 |
|
August 15, 2006 |
January 16, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
| 34 |
NCT00309907 |
Completed
Has Results |
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant |
- Accelerated Phase Chronic Myelogenous Leukemia
- Blastic Phase Chronic Myelogenous Leukemia
- Childhood Acute Lymphoblastic Leukemia in Remission
- (and 22 more...)
|
- Biological: etanercept
- Drug: methylprednisolone
|
Interventional |
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28.
- Survival Rate
- Estimate Percentage Pulmonary Response in Patients With IPS Treated With Etanercept + Corticosteroid Therapy
- (and 3 more...)
|
39 |
All |
1 Year to 17 Years (Child) |
NCT00309907 |
ASCT0521
NCI-2009-00429
COG-PBMTC-SUP051
COG-ASCT0521
CDR0000456407
U10CA098543 |
|
April 2006 |
September 2011 |
September 2011 |
April 3, 2006 |
September 29, 2017 |
February 14, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Children's Oncology Group
Arcadia, California, United States - Loma Linda University Medical Center
Loma Linda, California, United States - (and 23 more...)
|
| 35 |
NCT00217412 |
Completed |
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia |
- Childhood Acute Promyelocytic Leukemia (M3)
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Burkitt Lymphoma
- (and 16 more...)
|
- Drug: vorinostat
- Drug: isotretinoin
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities DLT graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- The proportion of patients who demonstrate each polymorphism
|
60 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00217412 |
NCI-2012-01821
CDR0000440999
COG-ADVL0416
NCI-06-C-0254
ADVL0416 |
|
August 2005 |
September 2009 |
September 2009 |
September 22, 2005 |
June 17, 2014 |
|
- Children's Oncology Group
Philadelphia, Pennsylvania, United States
|
| 36 |
NCT00118352 |
Completed
Has Results |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
- Acute Undifferentiated Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 61 more...)
|
- Biological: alemtuzumab
- Radiation: total-body irradiation
- Drug: fludarabine phosphate
- (and 6 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Grade III-IV Acute GVHD
- Incidence of Graft Rejection
- Incidence of High-dose Corticosteroid Utilization.
- (and 4 more...)
|
12 |
All |
up to 74 Years (Child, Adult, Senior) |
NCT00118352 |
1959.00
NCI-2009-01496
P01CA018029
P30CA015704 |
|
March 2005 |
July 2010 |
May 26, 2015 |
July 11, 2005 |
May 30, 2017 |
May 30, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States - University of Torino
Torino, Italy
|
| 37 |
NCT00101270 |
Completed |
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Diffuse Large Cell Lymphoma
- (and 26 more...)
|
- Drug: irinotecan hydrochloride
- Drug: oxaliplatin
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT
- Overall response assessed using RECIST criteria
|
24 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00101270 |
NCI-2012-01819
ADVL0415
CDR0000401518
COG-ADVL0415
U01CA097452 |
|
March 2005 |
September 2007 |
|
January 10, 2005 |
June 5, 2013 |
|
- COG Phase I Consortium
Arcadia, California, United States
|
| 38 |
NCT00101205 |
Terminated |
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
- Angioimmunoblastic T-cell Lymphoma
- B-cell Childhood Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- (and 24 more...)
|
- Drug: oxaliplatin
- Drug: etoposide
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of the combination of oxaliplatin and etoposide assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- MTD of the addition of ifosfamide to the combination of oxaliplatin and etoposide assessed by CTCAE version 3.0
|
40 |
All |
up to 21 Years (Child, Adult) |
NCT00101205 |
NCI-2009-00075
CDR0000405828
OXALET
6634
P30CA021765 |
|
November 2004 |
January 2012 |
|
January 10, 2005 |
February 24, 2014 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 39 |
NCT00006251 |
Active, not recruiting |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
- Acute Undifferentiated Leukemia
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- (and 61 more...)
|
- Radiation: total-body irradiation
- Drug: fludarabine phosphate
- Drug: cyclosporine
- (and 5 more...)
|
Interventional |
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Risk of graft rejection defined as the absence of detectable peripheral blood donor T cells with the addition of fludarabine phosphate
- Incidence of acute grade II/IV GVHD
- Incidence of chronic GVHD
- (and 5 more...)
|
21 |
All |
up to 74 Years (Child, Adult, Senior) |
NCT00006251 |
1533.00
NCI-2013-01634
P01CA078902
P30CA015704 |
|
May 2000 |
September 2005 |
|
June 9, 2004 |
August 10, 2017 |
|
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States - University of Torino
Torino, Italy
|
| 40 |
NCT00036855 |
Terminated |
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma |
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Primary CNS Lymphoma
- Post-transplant Lymphoproliferative Disorder
- (and 4 more...)
|
- Biological: rituximab
- Radiation: indium In 111 ibritumomab tiuxetan
- Radiation: yttrium Y 90 ibritumomab tiuxetan
- (and 3 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD, defined as that dose at which fewer than one-third of patients experience DLT graded according to the NCI CTC v 2.0
|
36 |
All |
up to 21 Years (Child, Adult) |
NCT00036855 |
NCI-2012-01871
ADVL0013
U01CA097452
CDR0000069331 |
|
June 2002 |
March 2005 |
|
January 27, 2003 |
January 17, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
| 41 |
NCT00058461 |
Terminated |
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
- B-cell Childhood Acute Lymphoblastic Leukemia
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- (and 6 more...)
|
- Drug: ifosfamide
- Drug: etoposide
- Biological: rituximab
- (and 5 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate determined by physical exam and appropriate imaging studies
- Relapse-free survival rate
- Toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
- CD34 cells mobilization by flow cytometry
|
82 |
All |
up to 21 Years (Child, Adult) |
NCT00058461 |
NCI-2012-01804
COG-ANHL0121
CDR0000298751
ANHL0121
U10CA098543 |
|
November 2003 |
March 2007 |
|
April 9, 2003 |
October 8, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
| 42 |
NCT00049504 |
Completed
Has Results |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 94 more...)
|
- Drug: cyclophosphamide
- Drug: fludarabine phosphate
- Drug: tacrolimus
- (and 8 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Donor Engraftment (Chimerism)
- Incidence of Grades III-IV Acute GVHD
- Non-relapse-related Mortality
|
53 |
All |
Child, Adult, Senior |
NCT00049504 |
1667.00
NCI-2010-00166 |
|
January 2002 |
March 2011 |
February 2014 |
January 27, 2003 |
May 17, 2017 |
May 17, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 43 |
NCT00040846 |
Active, not recruiting
Has Results |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- (and 97 more...)
|
- Biological: alemtuzumab
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- (and 4 more...)
|
Interventional |
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the Risk of Transplant Related Mortality.
- Evaluate the Risk of Occurrence of Acute and Chronic GVHD
- Determine Whether Engraftment Can be Maintained With a Single Dose Fludarabine, DLI and Continued MMF/CSP, Defined as Rejection Rate < 20%.
- (and 2 more...)
|
60 |
All |
up to 74 Years (Child, Adult, Senior) |
NCT00040846 |
1591.00
NCI-2011-00471
P30CA015704
P01CA018029 |
|
November 2001 |
December 2009 |
|
January 27, 2003 |
April 24, 2017 |
March 16, 2017 |
- Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, United States - Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States - LDS Hospital
Salt Lake City, Utah, United States - (and 4 more...)
|
| 44 |
NCT00014235 |
Active, not recruiting |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
- Acute Undifferentiated Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- (and 74 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Procedure: peripheral blood stem cell transplantation
- (and 4 more...)
|
Interventional |
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Probability of severe (grade III/IV) GVHD in each arm
- Incidence of graft rejection
- Incidence of non-relapse mortality
- (and 2 more...)
|
160 |
All |
up to 74 Years (Child, Adult, Senior) |
NCT00014235 |
1596.00
NCI-2012-00671
P30CA015704 |
|
December 2000 |
February 2005 |
|
January 27, 2003 |
November 22, 2017 |
|
- University of Arizona Health Sciences Center
Tucson, Arizona, United States - City of Hope Medical Center
Duarte, California, United States - Stanford University Hospitals and Clinics
Stanford, California, United States - (and 8 more...)
|
| 45 |
NCT00012181 |
Completed |
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas |
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- (and 19 more...)
|
- Drug: alvocidib
- Other: pharmacological study
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using Common Toxicity Criteria version 2.0
|
30 |
All |
up to 21 Years (Child, Adult) |
NCT00012181 |
NCI-2012-01854
ADVL0017
CCG-AO972
CDR0000068491
COG-ADVL0017
NCI-A0972
U01CA097452 |
|
April 2001 |
January 2005 |
|
January 27, 2003 |
July 2, 2013 |
|
- COG Phase I Consortium
Arcadia, California, United States
|
| 46 |
NCT00003575 |
Completed |
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma |
|
- Biological: filgrastim
- Biological: recombinant interleukin-12
- Drug: etoposide
- Drug: ifosfamide
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00003575 |
NCI-2012-02276
AMC-008
CDR0000066642 |
|
January 1999 |
April 2002 |
|
May 20, 2004 |
February 8, 2013 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - San Francisco General Hospital Medical Center
San Francisco, California, United States - Sylvester Cancer Center, University of Miami
Miami, Florida, United States - (and 7 more...)
|
| 47 |
NCT00003217 |
Completed |
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
- Biological: filgrastim
- Drug: cyclophosphamide
- Drug: cytarabine
- (and 4 more...)
|
Interventional |
Phase 1 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
20 |
All |
up to 21 Years (Child, Adult) |
NCT00003217 |
9517
POG-9517
CDR0000066078 |
|
March 1998 |
October 2004 |
September 2006 |
September 6, 2004 |
July 25, 2014 |
|
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Lucile Packard Children's Hospital at Stanford
Palo Alto, California, United States - Children's Memorial Hospital, Chicago
Chicago, Illinois, United States - (and 11 more...)
|
| 48 |
NCT00068302 |
Terminated |
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma |
|
|
Interventional |
Phase 1 |
- Children's Hospital of Philadelphia
- National Childhood Cancer Foundation
- The Leukemia and Lymphoma Society
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity as assessed by Common Toxicity Criteria (CTC) toxicity criteria after the first course of treatment
- Response as assessed by radiologic scans after each course of treatment
|
10 |
All |
up to 21 Years (Child, Adult) |
NCT00068302 |
CDR0000321392
CHP-755
CHP-IRB-2002-12-3086 |
|
January 2003 |
April 2009 |
July 2013 |
September 11, 2003 |
March 12, 2015 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 49 |
NCT00003595 |
Completed |
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma |
|
- Biological: filgrastim
- Biological: rituximab
- Drug: CHOP regimen
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT00003595 |
NCI-2012-02279
AMC-010
CPMC-IRB-9691
CWRU-AMC-1400
UCLA-9810029
CDR0000066666 |
|
January 1999 |
April 2006 |
|
October 28, 2003 |
February 8, 2013 |
|
- USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - San Francisco General Hospital Medical Center
San Francisco, California, United States - (and 10 more...)
|
| 50 |
NCT00002738 |
Completed |
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma |
|
- Drug: leucovorin calcium
- Drug: trimetrexate glucuronate
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
25 |
All |
up to 21 Years (Child, Adult) |
NCT00002738 |
95-093
P30CA008748
MSKCC-95093
NCI-V96-0840 |
|
January 1996 |
June 2006 |
June 2006 |
January 27, 2003 |
March 7, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
Create an RSS feed from your search for:
Download the search results for: